IONS is the most pressured name among its closest biotech peers right now. Short interest has climbed to 13.2% of free float, a level that places it well above correlated names such as ARWR at mid-single digits and NTLA, where positioning is similarly elevated but price damage has been shallower. The stock lost 9.4% over the past week, roughly three…
IONS BMO Capital upgrades to Outperform, raises PT to $66 from $54, implying 49% upside from $44.27 close. Consensus target now $82.91.
Key data as of 11 Nov 2026
IONS BMO Capital upgrades to Outperform, raises PT to $66 from $54, implying 49% upside from $44.27 close. Consensus target now $82.91.
2 Analyst updates in 30 days
IONS retail attention hits 5.4 standard deviations above its own 90-day history, per Wikipedia views and ORTEX stock page data, signaling outsized interest as of October 19.
Ionis Pharmaceuticals heads into this week's earnings report with short interest at an 11-month high and the analyst community in near-uniform target-cutting mode — a combination that frames today's results as a…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for IONS — free to start on ORTEX.
Sign up for free →Open IONS on ORTEX